A RetroSearch Logo

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Search Query:

Showing content from https://link.springer.com/doi/10.1007/s00520-011-1226-5 below:

Electrocardiographic findings of palonosetron in cancer patients

References

  1. Navari RM (2009) Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist. Expert Opin Drug Metab Toxicol 5:1577–1586

    Article  PubMed  CAS  Google Scholar 

  2. Audhuy B, Cappelaere P, Martin M, Cervantes A, Fabbro M, Rivière A, Khayat D, Bleiberg H, Faraldi M, Claverie N, Aranda E, Auclerc G, Audhuy B, Benhammouda A, Bleiberg H, Cals L, Cappelaere P, Cattan A, Cervantes A, Chevallier B, Conroy T, Cupissol D, De Grève J, Diaz-Rubio E, Seitz JF et al (1996) A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 32A:807–813

    PubMed  CAS  Google Scholar 

  3. Navari RM (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting—two new agents. J Support Oncol 1:89–103

    PubMed  CAS  Google Scholar 

  4. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473–2482

    Article  PubMed  CAS  Google Scholar 

  5. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570–1577

    Article  PubMed  CAS  Google Scholar 

  6. Decker GM, DeMeyer ES, Kisko DL (2006) Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 4:35–41

    PubMed  Google Scholar 

  7. Yu Z, Liu W, Wang L, Liang H, Huang Y, Si X, Zhang H, Liu D, Zhang H (2009) The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Canc 17:99–102

    Article  Google Scholar 

  8. Watanabe H, Hasegawa A, Shinozaki T, Arita S, Chigira M (1995) Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Canc Chemother Pharmacol 35:278–282

    Article  CAS  Google Scholar 

  9. Boike SC, Ilson B, Zariffa N, Jorkasky DK (1997) Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm 54:1172–1176

    PubMed  CAS  Google Scholar 

  10. Benedict CR, Arbogast R, Martin L, Patton L, Morrill B, Hahne W (1996) Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 28:53–59

    Article  PubMed  CAS  Google Scholar 

  11. Perzanowski C, Ho AT, Jacobson AK (2005) Increased P-wave dispersion predicts recurrent atrial fibrillation after cardioversion. J Electrocardiol 38:43–46

    Article  PubMed  Google Scholar 

  12. Chen A, Kusumoto FM (2004) QT dispersion: much ado about something? Chest 125:1974–1977

    Article  PubMed  Google Scholar 

  13. Day CP, McComb JM, Campbell RW (1990) QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 63:342–344

    Article  PubMed  CAS  Google Scholar 

  14. Perkiomaki JS, Huikuri HV, Koistinen JM, Makikallio T, Castellanos A, Myerburg RJ (1997) Heart rate variability and dispersion of QT interval in patients with vulnerability to ventricular tachycardia and ventricular fibrillation after previous myocardial infarction. Am Coll Cardiol 30:1331–1338

    Article  CAS  Google Scholar 

  15. Morganroth J (2007) Evaluation of the effect on cardiac repolarization (QTc interval) of oncologic drugs. Ernst Schering Res Found Workshop 59:171–184

    Article  PubMed  Google Scholar 

  16. Bazett HC (1920) An analysis of the time-relations of electrocardiograms. Heart 7:353–370

    Google Scholar 

  17. Yavas O, Yazici M, Eren O, Boruban C, Artac M, Genc M (2008) The acute effect of tropisetron on ECG parameters in cancer patients. Support Care Canc 16:1011–1015

    Article  Google Scholar 

  18. Hunt TL, Cramer M, Shah A, Stewart W, Benedict CR, Hahne WF (1995) A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmacol 35:705–712

    PubMed  CAS  Google Scholar 

  19. Gray GW, McLellan TM, Ducharme MB (1996) Granisetron shows no pro-arrhythmic effect in normal subjects during or after exercise in a hot environment. Aviat Space Environ Med 67:759–761

    PubMed  CAS  Google Scholar 

  20. Jantunen IT, Kataja VV, Muhonen TT, Parviainen T (1996) Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol 37:502–504

    Article  PubMed  CAS  Google Scholar 

  21. Grote TH, Pineda LF, Figlin RA, Pendergrass KB, Hesketh PJ, Karlan BY, Reeves JA, Porter LL, Benedict CR, Hahne WF (1997) Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group. Cancer J Sci Am 3:45–51

    PubMed  CAS  Google Scholar 

  22. Rubenstein EB, Gralla RJ, Hainsworth JD, Hesketh PJ, Grote TH, Modiano MR, Khojasteh A, Kalman LA, Benedict CR, Hahne WF (1997) Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group. Cancer 79:1216–1224

    Article  PubMed  CAS  Google Scholar 

  23. Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, Anthony L, Khojasteh A, Tapazoglou E, Benedict C, Hahne W (1996) Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol 14:2242–2249

    PubMed  CAS  Google Scholar 

  24. Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C (1997) Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 15:2966–2973

    PubMed  CAS  Google Scholar 

  25. Buyukavci M, Olgun H, Ceviz N (2005) The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol 28:201–204

    Article  PubMed  CAS  Google Scholar 

  26. Keefe DL (2002) The cardiotoxic potential of the 5-HT3 receptor antagonist antiemetics: is there cause for concern? Oncologist 7:65–72

    Article  PubMed  CAS  Google Scholar 

  27. Nishio H, Fujii A, Nakata Y (1996) Re-examination for pharmacological properties of serotonin-induced tachycardia in isolated guinea-pig atrium. Behav Brain Res 73:301–304

    Article  PubMed  CAS  Google Scholar 

  28. Aapro M, Rabaeus MR (2005) The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol 28:634–635

    Article  PubMed  Google Scholar 

  29. Sevimli S, Arslan Ş, Gündoğdu F, Aksakal E, Taş H, Gürlertop Y et al (2007) Konjestif kalp yetersizliği olan hastalarda karvedilol tedavisi QT dispersiyonunda düzelme sağlamaktadır. Turk Kardiyol Dern Ars 35:284–288

    Google Scholar 

  30. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin A et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441–1449

    Article  PubMed  CAS  Google Scholar 

  31. Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi (2004) Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 15:330–337

    Article  PubMed  CAS  Google Scholar 

  32. Coop AJ (2003) Comment: electrocardiogrphic and cardiovascular effects of the 5-hydroxytryptamine-3 resector antagonists. Ann Pharmacother 37:1918

    Article  PubMed  Google Scholar 

  33. Aapro MS, Macciocchi A, Gridelli C (2005) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. J Support Oncol 3:369–374

    PubMed  CAS  Google Scholar 

Download references

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.4